Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Lymphoid 1Breast 1

Conditions

Melanoma 38Carcinoma, Renal Cell 12Carcinoma, Non-Small-Cell Lung 12Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 8Carcinoma, Merkel Cell 8Uterine Cervical Neoplasms 7Stomach Neoplasms 7Colorectal Neoplasms 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Small Cell Lung Carcinoma 5Neoplasms 5Kidney Neoplasms 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Esophageal Neoplasms 3Breast Neoplasms 3Urogenital Neoplasms 2Skin Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Neoplasms by Histologic Type 2Microsatellite Instability 2Mesothelioma, Malignant 2Mesothelioma 2Lymphoma 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Squamous Cell 2

Interventions

pembrolizumab 3Nivolumab 3fludarabine 2atezolizumab 2Cyclophosphamide 2fludarabine phosphate 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Carboxylesterase 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Microsatellite Instability × atezolizumab × Dermatologic × Clear all
NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡